Inhibition of PARP activation by enalapril is crucial for its renoprotective effect in cisplatin-induced nephrotoxicity in rats

References

• Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265–7279.
   PubMed Web of Science ®Google Scholar
• Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008;73:994–1007.
   PubMed Web of Science ®Google Scholar
• Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003;23:460–464.
   PubMed Web of Science ®Google Scholar
• Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2010;2:2490–2518.
   PubMed Web of Science ®Google Scholar
• Virag L, Szabo C. The therapeutic potential of poly (ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002;54:375–429.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Horváth B, Kechrid M, Tanchian G, Rajesh M, Naura AS, et al. Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury. Free Radic Biol Med 2011;51: 1774–1788.
   PubMed Web of Science ®Google Scholar
• Kim J, Long KE, Tang K, Padanilam BJ. Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity. Kidney Int 2012;82:193–203.
   PubMed Web of Science ®Google Scholar
• Park S, Yoon SP, Kim J. Cisplatin induces primary necrosis through poly(ADP-ribose) polymerase 1 activation in kidney proximal tubular cells. Anat Cell Biol 2015;48:66–74.
   PubMed Web of Science ®Google Scholar
• Racz I, Tory K, Gallyas F Jr, Berente Z, Osz E, Jaszlits L, et al. BGP-15 – a novel poly(ADP-ribose) polymerase inhibitor – protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem Pharmacol 2002;63:1099–1111.
   PubMed Web of Science ®Google Scholar
• Asmussen S, Bartha E, Olah G, Sbrana E, Rehberg SW, Yamamoto Y, et al. The angiotensin-converting enzyme inhibitor captopril inhibits poly(ADP-ribose) polymerase activation and exerts beneficial effects in an ovine model of burn and smoke injury. Shock 2011;36:402–409.
   PubMed Web of Science ®Google Scholar
• Szabó C, Pacher P, Zsengellér Z, Vaslin A, Komjáti K, Benkö R, et al. Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation. Mol Med 2004;10:28–35.
   PubMed Web of Science ®Google Scholar
• Zhou TB, Jiang ZP. Role of poly (ADP-ribose)-polymerase and its signaling pathway with renin-angiotensin aldosterone system in renal diseases. J Recept Signal Transduct Res 2014;34:143–148.
   PubMed Web of Science ®Google Scholar
• Feld LG, Cachero S, Van Liew JB, Zamlauski-Tucker M, Noble B. Enalapril and renal injury in spontaneously hypertensive rats. Hypertension 1990;16:544–554.
   PubMed Web of Science ®Google Scholar
• de Cavanagh EM, Inserra F, Toblli J, Stella I, Fraga CG, Ferder L. Enalapril attenuates oxidative stress in diabetic rats. Hypertension 2001;38:1130–1136.
   PubMed Web of Science ®Google Scholar
• Ishidoya S, Morrissey J, McCracken R, Klahr S. Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy. Kidney Int 1996;49:1110–1119.
   PubMed Web of Science ®Google Scholar
• Bilan VP, Salah EM, Bastacky S, Jones HB, Mayers RM, Zinker B, et al. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats. J Endocrinol 2011;210:293–308.
   PubMed Web of Science ®Google Scholar
• Zafar I, Tao Y, Falk S, McFann K, Schrier RW, Edelstein C. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol 2007;293:F854–F859.
   PubMed Web of Science ®Google Scholar
• Adamczak M, Gross ML, Krtil J, Koch A, Tyralla K, Amann K, Ritz E. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 2003;14:2833–2842.
   PubMed Web of Science ®Google Scholar
• Hari P, Sahu J, Sinha A, Pandey RM, Bal CS, Bagga A. Effect of enalapril on glomerular filtration rate and proteinuria in children with chronic kidney disease: a randomized controlled trial. Indian Pediatr 2013;50:923–928.
   PubMed Web of Science ®Google Scholar
• Björck S, Mulec H, Johnsen SA, Nordén G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992;304:339–343.
   PubMed Web of Science ®Google Scholar
• Martínez-Castelao A, Hueso M, Sanz V, Rejas J, Alsina J, Grinyó JM. Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin. Kidney Int 1998;68:S130–S134.
   Google Scholar
• Chandran G, Sirajudeen KN, Yusoff NS, Swamy M, Samarendra MS. Effect of the antihypertensive drug enalapril on oxidative stress markers and antioxidant enzymes in kidney of spontaneously hypertensive rat. Oxid Med Cell Longev 2014;2014:608512.
   PubMed Web of Science ®Google Scholar
• Kim JM, Heo HS, Choi YJ, Ye BH, Mi Ha Y, Seo AY, et al. Inhibition of NF-κB-induced inflammatory responses by angiotensin II antagonists in aged rat kidney. Exp Gerontol 2011;46:542–548.
   PubMed Web of Science ®Google Scholar
• Kushwaha S, Vikram A, Jena GB. Protective effects of enalapril in streptozotocin-induced diabetic rat: studies of DNA damage, apoptosis and expression of CCN2 in the heart, kidney and liver. J Appl Toxicol 2012;32:662–672.
   PubMed Web of Science ®Google Scholar
• Moron MS, Depierre JW, Manmerik B. Level of glutathione, glutathione reductase and glutathione-s-transferase activity in rat lung and liver. Biochim Biophys Acta 1979;582:67–78.
   PubMed Web of Science ®Google Scholar
• Ohkawa H, Ohishi N, Yagi N. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95:351–358.
   PubMed Web of Science ®Google Scholar
• Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974;47:469–474.
   PubMedGoogle Scholar
• Aebi H. Catalase. In: Bergmeyer HU, ed. Methods of enzymatic analysis. New York: Academic Press Inc.; 1974;673–685.
   Google Scholar
• Terada Y, Inoue K, Matsumoto T, Ishihara M, Hamada K, Shimamura Y, et al. 5-Aminolevulinic acid protects against cisplatin-induced nephrotoxicity without compromising the anticancer efficiency of cisplatin in rats in vitro and in vivo. PLoS One 2013;8:e80850.
   PubMed Web of Science ®Google Scholar
• Devalaraja-Narashimha K, Singaravelu K, Padanilam BJ. Poly(ADP-ribose) polymerase-mediated cell injury in acute renal failure. Pharmacol Res 2005;52:44–59.
   PubMed Web of Science ®Google Scholar
• Giansanti V, Donà F, Tillhon M, Scovassi AI. PARP inhibitors: new tools to protect from inflammation. Biochem Pharmacol 2010;80:1869–1877.
   PubMed Web of Science ®Google Scholar
• Zamani Z, Nematbakhsh M, Eshraghi-Jazi F, Talebi A, Jilanchi S, Navidi M, et al. Effect of enalapril in cisplatin-induced nephrotoxicity in rats; gender-related difference. Adv Biomed Res 2016;5:14.
   PubMedGoogle Scholar
• Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009;61:223–242.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Lee JH, Kim SJ, Oh GS, Moon HD, Kwon KB, et al. Roles of NADPH oxidases in cisplatin-induced reactive oxygen species generation and ototoxicity. J Neurosci 2010;30:3933–3946.
   PubMed Web of Science ®Google Scholar
• El-Sayed el-SM, Abd-Ellah MF, Attia SM. Protective effect of captopril against cisplatin-induced nephrotoxicity in rats. Pak J Pharm Sci 2008;21:255–261.
   PubMed Web of Science ®Google Scholar
• Costa JC, Costa RS, Silva CG, Coimbra TM. Enalapril reduces the expression of nuclear factor-kappa B and c-Jun N-terminal kinase in the renal cortices of five-sixths-nephrectomized rats. Am J Nephrol 2006;26:281–286.
   PubMed Web of Science ®Google Scholar
• Servais H, Ortiz A, Devuyst O, Denamur S, Tulkens PM, Mingeot-Leclercq MP. Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation. Apoptosis 2008;13:11–32.
   PubMed Web of Science ®Google Scholar
• Yano T, Itoh Y, Matsuo M, Kawashiri T, Egashira N, Oishi R. Involvement of both tumor necrosis factor-alpha-induced necrosis and p53-mediated caspase-dependent apoptosis in nephrotoxicity of cisplatin. Apoptosis 2007;12:1901–1909.
   PubMed Web of Science ®Google Scholar
• Jiang M, Dong Z. Regulation and pathological role of p53 in cisplatin nephrotoxicity. J Pharmacol Exp Ther 2008;327:300–307.
   PubMed Web of Science ®Google Scholar
• Wieler S, Gagné JP, Vaziri H, Poirier GG, Benchimol S. Poly(ADP-ribose) polymerase-1 is a positive regulator of the p53-mediated G1 arrest response following ionizing radiation. J Biol Chem 2003;278:18914–18921.
   PubMed Web of Science ®Google Scholar